Project Description

Alzheimer’s disease (AD) is the most common progressive neurodegenerative disorder among elderly people. Early diagnosis and intervention to delay the onset of AD are beneficial for patients and their carers and can substantially support the healthcare systems. In the past few years, it has been established that the aggregation of amyloid-beta (Aβ) peptides, particularly Aβ1-42 peptide, has been accepted as a prominent biomarker for the early diagnosis of AD

In the current work, an innovative and facile solution is proposed that aims at the development of functionalized MXenes based platform for the development of labelled (sandwich assay format) and label-free electrochemical immunosensors towards the detection of Aβ1-42 in the plasma/serum samples. The label-free electrochemical immunosensor will be fabricated by covalently immobilizing the capture antibody (specific to Aβ1-42) on functionalized MXenes modified electrodes. Validation of the developed immunosensor will be carried out by comparing the results obtained from our newly devised sensor with the standard ELISA test using spiked plasma/serum samples.